NEW YORK (GenomeWeb) – Sunnyvale, California-based InSilixa has received funding to develop a point-of-care rapid molecular diagnostic assay for oral human papillomavirus detection, the company announced today.

The $224,764 Phase I Small Business Innovation Research grant was awarded by the National Institutes of Health.

The assay is "a potential new tool to screen oral specimens such as saliva for cancer-causing HPV types and to risk stratify those persons found to be positive,” Gary Schoolnik, chief medical officer of InSilixa, said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.

Nov
14
Sponsored by
PerkinElmer

In these times of economic constraint and increasing research costs, shared resource cores have become a cost-effective and essential platform for researchers who seek to investigate complex translational research questions.